Print page |
E-mail page
| 
Download PDF
|
Add to briefcase
« Previous Release | Next Release »
EAST BRUNSWICK, N.J., Oct 27, 2009 (GlobeNewswire via COMTEX News Network) -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) today announced that Paul Hamelin, President of Savient Pharmaceuticals will be presenting at the upcoming Oppenheimer 20th Annual Healthcare Conference on November 3rd, 2009.
The presentation is scheduled to begin on Tuesday, November 3, 2009 at 1:35 p.m. Eastern Time. The conference will be held at The Waldorf Astoria in New York, NY, November 3-4, 2009.
Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' Web site at http://www.savient.com. A replay of the webcast will be available on the Company's Web site for 30 days.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.
SVNT - G
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Savient Pharmaceuticals Inc
CONTACT: Savient Pharmaceuticals, Inc. Mary Coleman (732) 418-9300 information@savient.com Burns McClellan Susan Neath (212) 213-0006 sneath@burnsmc.com
(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
News Provided by COMTEX